4.5 Article

Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines

期刊

FUTURE MEDICINAL CHEMISTRY
卷 10, 期 7, 页码 823-835

出版社

FUTURE SCI LTD
DOI: 10.4155/fmc-2017-0298

关键词

acute myeloid leukemia; drug resistance; FLT3-ITD; secondary mutations; TOPK

资金

  1. Purdue University, Purdue Cancer Center
  2. Elks Foundation
  3. NIH [P30 CA023168]
  4. NATIONAL CANCER INSTITUTE [P30CA023168] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Aim: Approximately 30% of acute myeloid leukemia (AML) patients carry FLT3 tyrosine kinase domain (TKD) mutations or internal tandem duplication (FLT3-ITD). Currently there is a paucity of compounds that are active against drug-resistant FLT3-ITD, which contains secondary mutations in the TKD, mainly at residues D835/F691. Results: HSD1169, a novel compound, is active against FLT3-ITD (D835 or F691). HSD1169 is also active against T-LAK cell-originated protein kinase (TOPK), a collaborating kinase that is highly expressed in AML cell lines. HSD1169 was active against MV4-11 and Molm-14 (FLT3-ITD cell lines) but not NOMO-1 or HL60 (FLT3-WT cell lines). HSD1169 was also active against sorafenib-resistant Molm13-res cell line (containing FLT3-ITD/D835Y). Conclusion: HSD1169 or an analog could become a therapeutic agent for AML containing drug-resistant FLT3-ITD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据